IN2014CN02887A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02887A IN2014CN02887A IN2887CHN2014A IN2014CN02887A IN 2014CN02887 A IN2014CN02887 A IN 2014CN02887A IN 2887CHN2014 A IN2887CHN2014 A IN 2887CHN2014A IN 2014CN02887 A IN2014CN02887 A IN 2014CN02887A
- Authority
- IN
- India
- Prior art keywords
- patient
- multiple myeloma
- solid tumor
- hodgkin lymphoma
- non hodgkin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161549034P | 2011-10-19 | 2011-10-19 | |
US201261591401P | 2012-01-27 | 2012-01-27 | |
US201261647233P | 2012-05-15 | 2012-05-15 | |
US201261653436P | 2012-05-31 | 2012-05-31 | |
PCT/US2012/060723 WO2013059396A2 (fr) | 2011-10-19 | 2012-10-18 | Traitement du cancer avec des inhibiteurs de la kinase tor |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN02887A true IN2014CN02887A (fr) | 2015-07-03 |
Family
ID=47116477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2887CHN2014 IN2014CN02887A (fr) | 2011-10-19 | 2012-10-18 |
Country Status (19)
Country | Link |
---|---|
US (4) | US9493466B2 (fr) |
EP (3) | EP3659599B1 (fr) |
JP (5) | JP2014530861A (fr) |
KR (1) | KR101978537B1 (fr) |
CN (2) | CN107157990B (fr) |
BR (1) | BR112014009755B1 (fr) |
CA (1) | CA2852921C (fr) |
EA (2) | EA030664B1 (fr) |
ES (2) | ES2894958T3 (fr) |
HK (1) | HK1243919A1 (fr) |
IL (3) | IL232128B (fr) |
IN (1) | IN2014CN02887A (fr) |
MX (3) | MX348566B (fr) |
MY (1) | MY183661A (fr) |
SG (3) | SG11201401630SA (fr) |
TW (4) | TWI629983B (fr) |
UA (1) | UA115319C2 (fr) |
WO (1) | WO2013059396A2 (fr) |
ZA (2) | ZA201402771B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
EP2945636B1 (fr) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux |
AU2014223501A1 (en) * | 2013-02-28 | 2015-09-17 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
MX2015014589A (es) * | 2013-04-17 | 2016-04-25 | Signal Pharm Llc | Tratamiento de cancer con dihidropirazino-pirazinas. |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
JP6382949B2 (ja) * | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法 |
MX2015014596A (es) * | 2013-04-17 | 2016-03-03 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. |
BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
WO2014172426A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Traitement du cancer par des dihydropyrazino-pyrazines |
WO2014172432A1 (fr) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Polythérapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer |
EA029072B1 (ru) * | 2013-04-17 | 2018-02-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
CN105792816A (zh) * | 2013-10-04 | 2016-07-20 | 西格诺药品有限公司 | 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂 |
US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
WO2016010886A1 (fr) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Méthodes de traitement d'un cancer à l'aide de composés de pyrrolopyrimidine substitués, compositions de ceux-ci |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
WO2017136689A1 (fr) * | 2016-02-05 | 2017-08-10 | Academia Sinica | Composés purine présentant une activité anticancéreuse |
WO2018013430A2 (fr) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Composés hétérocycliques pour le traitement d'une infection à arenavirus |
JOP20190151B1 (ar) | 2016-12-20 | 2023-09-17 | Astrazeneca Ab | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان |
IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
EP3704229B1 (fr) * | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Procédé pour la production d'une composition de lymphocytes t |
EP3762385A4 (fr) | 2018-03-09 | 2021-11-24 | Recurium IP Holdings, LLC | L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées |
CN110526907B (zh) * | 2018-05-23 | 2021-04-23 | 四川大学 | 苯并噁嗪酮类衍生物及其应用 |
CA3147902A1 (fr) * | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Amides heterobicycliques servant d'inhibiteurs de cd38 |
JP2023503931A (ja) * | 2019-11-22 | 2023-02-01 | メッドシャイン ディスカバリー インコーポレイテッド | Dna-pk阻害剤としてのピリミドピロール系スピロ化合物及びその誘導体 |
JP7383818B2 (ja) * | 2019-11-25 | 2023-11-20 | ザイ ラボ (シャンハイ) カンパニー、リミテッド. | Dna-pk阻害剤としてのピリミドイミダゾル系化合物 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE262026C (fr) | ||||
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | 2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法 |
DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
TW274550B (fr) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
WO1999016438A1 (fr) | 1997-09-26 | 1999-04-08 | Asta Medica Aktiengesellschaft | Composes a base d'azabenzimidazole destines a la modulation d'une fonction de proteine kinase de serine/threonine |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | 2−アリールプリン−9−アセトアミド誘導体 |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | 2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体 |
BR0116113A (pt) | 2000-12-12 | 2004-08-03 | Neurogen Corp | Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas |
WO2002076954A1 (fr) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes |
CN1551881A (zh) | 2001-09-04 | 2004-12-01 | ���ָ��Ӣ��ķ�������Ϲ�˾ | 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途 |
CA2462441A1 (fr) | 2001-10-18 | 2003-04-24 | Pier F. Cirillo | Composes d'uree benzo fusionnes 1,4-disubstitues utilises comme inhibiteurs des cytokines |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
CN1653077A (zh) | 2002-05-06 | 2005-08-10 | 健亚生物科技公司 | 治疗c型肝炎病毒感染的核苷衍生物 |
US20040204420A1 (en) | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
WO2004041285A1 (fr) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Agents anti-inflammatoires |
DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
BR0318145A (pt) | 2003-02-26 | 2006-02-21 | Boehringer Ingelheim Pharma | dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
CA2522980A1 (fr) * | 2003-04-23 | 2004-11-04 | Wyeth Holdings Corporation | Derives de wortmannine solubles dans l'eau |
EP3521297B1 (fr) | 2003-05-30 | 2021-12-22 | Gilead Pharmasset LLC | Analogues de nucléoside fluorés modifiés |
JP4705912B2 (ja) | 2003-06-26 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾジアゼピンcgrp受容体拮抗物質 |
CA2569406A1 (fr) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methodes de traitement de troubles des mastocytes |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
WO2006001266A1 (fr) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | Procédé permettant de produire un dérivé de 2-arylpurine |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006036883A2 (fr) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Inhibiteurs imidazo{4,5-b}pyrazinone de proteines kinases |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
JP5118972B2 (ja) | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Hiv阻害性二環式ピリミジン誘導体 |
SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
WO2006065703A1 (fr) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyridopyrimidinones, dihydropyrimidopyrimidinones et pteridinones utiles en tant qu'inhibiteurs des kinases raf |
WO2006087530A1 (fr) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Composés chimiques |
WO2006091737A1 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulateurs de l'activite de gsk-3 |
EP1874772A1 (fr) | 2005-04-05 | 2008-01-09 | Pharmacopeia, Inc. | Derives de purine et d'imidazopyridine en vue d'une immunosuppression |
NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
PT2069352E (pt) * | 2006-08-02 | 2014-01-02 | Cytokinetics Inc | Certas entidades químicas, composições e métodos |
EP2364702A3 (fr) | 2006-09-05 | 2012-01-25 | Emory University | Inhibiteurs de kinase pour la prévention ou le traitement d'une infection |
WO2008030744A2 (fr) | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibiteurs de c-met et leurs utilisations |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008043031A1 (fr) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | Dérivés de 2-(benzimidazolyl) purine et de purinone substitués en position 6 pour immunosuppression |
EP2078016B1 (fr) * | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Composés hétéroaryle, compositions de ceux-ci et procédés de traitement avec ceux-ci |
BRPI0717773A2 (pt) | 2006-10-19 | 2013-11-05 | Signal Pharm Llc | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
WO2010056311A1 (fr) * | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases |
EP2379561B1 (fr) * | 2008-11-25 | 2015-11-04 | University Of Rochester | Inhibiteurs de mlk et procédés d'utilisation |
NZ599549A (en) | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
BR112012019459A2 (pt) * | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
US20120028972A1 (en) | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
CN103857804A (zh) | 2011-08-03 | 2014-06-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
CN104093398B (zh) | 2011-12-02 | 2017-03-15 | 西格诺药品有限公司 | 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法 |
-
2012
- 2012-10-18 WO PCT/US2012/060723 patent/WO2013059396A2/fr active Application Filing
- 2012-10-18 US US13/654,441 patent/US9493466B2/en active Active
- 2012-10-18 SG SG11201401630SA patent/SG11201401630SA/en unknown
- 2012-10-18 MX MX2014004775A patent/MX348566B/es active IP Right Grant
- 2012-10-18 SG SG10201505102WA patent/SG10201505102WA/en unknown
- 2012-10-18 EP EP20152170.5A patent/EP3659599B1/fr active Active
- 2012-10-18 MX MX2017002007A patent/MX357833B/es unknown
- 2012-10-18 EP EP18207204.1A patent/EP3466423B1/fr active Active
- 2012-10-18 ES ES18207204T patent/ES2894958T3/es active Active
- 2012-10-18 TW TW101138515A patent/TWI629983B/zh active
- 2012-10-18 JP JP2014537216A patent/JP2014530861A/ja active Pending
- 2012-10-18 EP EP12780374.0A patent/EP2768500B1/fr active Active
- 2012-10-18 ES ES12780374T patent/ES2751921T3/es active Active
- 2012-10-18 MY MYPI2017000252A patent/MY183661A/en unknown
- 2012-10-18 BR BR112014009755-0A patent/BR112014009755B1/pt active IP Right Grant
- 2012-10-18 CA CA2852921A patent/CA2852921C/fr active Active
- 2012-10-18 MX MX2020004689A patent/MX2020004689A/es unknown
- 2012-10-18 CN CN201710320646.1A patent/CN107157990B/zh active Active
- 2012-10-18 UA UAA201405225A patent/UA115319C2/uk unknown
- 2012-10-18 EA EA201490814A patent/EA030664B1/ru not_active IP Right Cessation
- 2012-10-18 EA EA201890768A patent/EA034512B1/ru not_active IP Right Cessation
- 2012-10-18 TW TW109119519A patent/TWI758746B/zh active
- 2012-10-18 TW TW106118908A patent/TWI708605B/zh active
- 2012-10-18 SG SG10201912850WA patent/SG10201912850WA/en unknown
- 2012-10-18 TW TW106118909A patent/TWI713752B/zh active
- 2012-10-18 CN CN201280062920.5A patent/CN103998036B/zh active Active
- 2012-10-18 IN IN2887CHN2014 patent/IN2014CN02887A/en unknown
- 2012-10-18 KR KR1020147012908A patent/KR101978537B1/ko active IP Right Grant
-
2014
- 2014-04-13 IL IL232128A patent/IL232128B/en active IP Right Grant
- 2014-04-15 ZA ZA2014/02771A patent/ZA201402771B/en unknown
- 2014-10-24 ZA ZA2014/07793A patent/ZA201407793B/en unknown
-
2016
- 2016-09-27 US US15/277,285 patent/US9937170B2/en active Active
- 2016-12-02 JP JP2016234951A patent/JP6360136B2/ja active Active
-
2018
- 2018-01-10 IL IL256828A patent/IL256828B/en active IP Right Grant
- 2018-02-20 US US15/899,706 patent/US11166950B2/en active Active
- 2018-03-09 HK HK18103366.0A patent/HK1243919A1/zh unknown
- 2018-06-21 JP JP2018117932A patent/JP2018162286A/ja active Pending
-
2020
- 2020-07-07 JP JP2020117028A patent/JP2020169203A/ja active Pending
-
2021
- 2021-03-01 IL IL281180A patent/IL281180B2/en unknown
- 2021-05-06 JP JP2021078559A patent/JP2021107461A/ja active Pending
- 2021-10-07 US US17/496,433 patent/US20220273650A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN02887A (fr) | ||
PH12018502234B1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502047A1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
MX355728B (es) | Inhibidores de cinasas. | |
PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
IN2014KN00769A (fr) | ||
MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
PH12015500867B1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2014013752A (es) | Inhibidores de nampt. | |
NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
MX348311B (es) | Inhibidores nampt. | |
IN2014CN04634A (fr) | ||
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
EP2768512A4 (fr) | Inhibiteur enzymatique pour le traitement du cancer | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |